I'll provide you with a list of the drugs. Some of the lists are extensive. The challenge is that in Canada, across the country, we basically do not see a form of public coverage for those same drugs. What we tend to see is that the drugs will have been reviewed by the common drug review and then, generally speaking, across most public plans, not reimbursed.
I mentioned 28% as being the average coverage that we see for these types of drugs here in Canada, whereas we're seeing in excess of 80% to 90% coverage in the other OECD countries for the drugs that will have been approved for use here.
So we're not seeing the same level of sophistication, maybe, in providing access to drugs in Canada's public plans as we see elsewhere in the OECD.